Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, … Read more
Market Cap & Net Worth: Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE:LLY) has a market capitalization of $711.91 Billion ($711.91 Billion ) as of July 14, 2025. Listed on the NYSE stock exchange, this USA-based company holds position #15 globally and #11 in its home market, demonstrating a 1.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Eli Lilly and Company's stock price $793.01 by its total outstanding shares 897736000 (897.74 Million).
Eli Lilly and Company Market Cap History: 1972 to 2025
Eli Lilly and Company's market capitalization history from 1972 to 2025. Data shows growth from $1.00 Billion to $ 711.91 Billion (13.60% CAGR).
Index Memberships
Eli Lilly and Company is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$2.19 Trillion | 32.44% | #1 of 24 |
|
S&P 500 Index
GSPC
|
$49.13 Trillion | 1.27% | #9 of 503 |
|
S&P 100
OEX
|
$34.64 Trillion | 1.81% | #9 of 101 |
Weight: Eli Lilly and Company's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Eli Lilly and Company Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Eli Lilly and Company's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
15.39x
Eli Lilly and Company's market cap is 15.39 times its annual revenue
0.53x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
65.44x
Eli Lilly and Company's market cap is 65.44 times its annual earnings
3.99x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $64.20 Billion | $19.96 Billion | $2.41 Billion | 3.22x | 26.66x |
| 2016 | $57.54 Billion | $21.22 Billion | $2.74 Billion | 2.71x | 21.02x |
| 2017 | $67.81 Billion | $19.97 Billion | -$204.10 Million | 3.39x | N/A |
| 2018 | $95.24 Billion | $21.49 Billion | $3.23 Billion | 4.43x | 29.47x |
| 2019 | $110.61 Billion | $22.32 Billion | $8.32 Billion | 4.96x | 13.30x |
| 2020 | $144.93 Billion | $24.54 Billion | $6.19 Billion | 5.91x | 23.40x |
| 2021 | $240.70 Billion | $28.32 Billion | $5.58 Billion | 8.50x | 43.12x |
| 2022 | $323.11 Billion | $28.54 Billion | $6.24 Billion | 11.32x | 51.74x |
| 2023 | $519.91 Billion | $34.12 Billion | $5.24 Billion | 15.24x | 99.21x |
| 2024 | $693.05 Billion | $45.04 Billion | $10.59 Billion | 15.39x | 65.44x |
Companies Similar to LLY by Market Capitalization
Companies near Eli Lilly and Company in the global market cap rankings as of July 14, 2025.
Key companies related to Eli Lilly and Company by market ranking:
- Berkshire Hathaway Inc (NYSE:BRK-A): Ranked #13 globally with a market cap of $873.47 Billion USD.
- JPMorgan Chase & Co (NYSE:JPM): Ranked #14 globally with a market cap of $751.35 Billion USD.
- Visa Inc. Class A (NYSE:V): Ranked #16 globally with a market cap of $594.38 Billion USD.
- Visa Inc. Cl A (LSE:0QZ0): Ranked #17 globally with a market cap of $593.89 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #13 | Berkshire Hathaway Inc | NYSE:BRK-A | $873.47 Billion | $712842.00 |
| #14 | JPMorgan Chase & Co | NYSE:JPM | $751.35 Billion | $286.86 |
| #16 | Visa Inc. Class A | NYSE:V | $594.38 Billion | $347.93 |
| #17 | Visa Inc. Cl A | LSE:0QZ0 | $593.89 Billion | $347.64 |
Eli Lilly and Company Historical Marketcap From 1972 to 2025
Between 1972 and today, Eli Lilly and Company's market cap moved from $1.00 Billion to $ 711.91 Billion, with a yearly change of 13.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $711.91 Billion | +2.72% |
| 2024 | $693.05 Billion | +33.30% |
| 2023 | $519.91 Billion | +60.91% |
| 2022 | $323.11 Billion | +34.24% |
| 2021 | $240.70 Billion | +66.07% |
| 2020 | $144.93 Billion | +31.03% |
| 2019 | $110.61 Billion | +16.14% |
| 2018 | $95.24 Billion | +40.45% |
| 2017 | $67.81 Billion | +17.83% |
| 2016 | $57.54 Billion | -10.37% |
| 2015 | $64.20 Billion | +25.39% |
| 2014 | $51.20 Billion | +39.75% |
| 2013 | $36.64 Billion | +7.29% |
| 2012 | $34.15 Billion | +24.26% |
| 2011 | $27.48 Billion | +25.18% |
| 2010 | $21.95 Billion | +3.66% |
| 2009 | $21.18 Billion | -6.24% |
| 2008 | $22.59 Billion | -21.33% |
| 2007 | $28.71 Billion | +5.69% |
| 2006 | $27.17 Billion | -5.18% |
| 2005 | $28.66 Billion | +2.53% |
| 2004 | $27.95 Billion | -17.54% |
| 2003 | $33.89 Billion | +13.14% |
| 2002 | $29.96 Billion | -17.57% |
| 2001 | $36.34 Billion | -14.42% |
| 2000 | $42.47 Billion | +41.89% |
| 1999 | $29.93 Billion | -24.24% |
| 1998 | $39.50 Billion | +29.12% |
| 1997 | $30.59 Billion | +93.51% |
| 1996 | $15.81 Billion | +32.65% |
| 1995 | $11.92 Billion | +77.33% |
| 1994 | $6.72 Billion | +15.63% |
| 1993 | $5.81 Billion | +2.45% |
| 1992 | $5.67 Billion | -24.88% |
| 1991 | $7.55 Billion | +16.99% |
| 1990 | $6.46 Billion | +9.50% |
| 1989 | $5.90 Billion | +64.13% |
| 1988 | $3.59 Billion | +12.81% |
| 1987 | $3.18 Billion | +7.49% |
| 1986 | $2.96 Billion | +36.80% |
| 1985 | $2.17 Billion | +75.76% |
| 1984 | $1.23 Billion | +19.75% |
| 1983 | $1.03 Billion | +5.13% |
| 1982 | $978.71 Million | +7.55% |
| 1981 | $910.03 Million | -8.34% |
| 1980 | $992.81 Million | +11.19% |
| 1979 | $892.89 Million | +29.45% |
| 1978 | $689.73 Million | +30.77% |
| 1977 | $527.42 Million | -17.39% |
| 1976 | $638.47 Million | -5.54% |
| 1975 | $675.91 Million | -22.77% |
| 1974 | $875.20 Million | -6.83% |
| 1973 | $939.39 Million | -6.16% |
| 1972 | $1.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 13th, 2025 the market cap of Eli Lilly and Company was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $711.91 Billion USD |
| MoneyControl | $711.91 Billion USD |
| MarketWatch | $711.91 Billion USD |
| MarketCap.Company | $711.91 Billion USD |
| Reuters | $711.91 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.